NASDAQ: PCSAProcessa Pharmaceuticals Inc Stock
$0.26+0.03 (+13.04%)
Updated Apr 30, 2025
PCSA Price
$0.26
Fair Value Price
$0.34
Market Cap
$1.36M
52 Week Low
$0.15
52 Week High
$3.10
P/E
-0.07x
P/B
0.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.9
Operating Cash Flow
-$11M
Beta
0.76
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PCSA Overview
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PCSA's potential to beat the market
- PCSA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PCSA
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important PCSA news, forecast changes, insider trades & much more!
PCSA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PCSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PCSA ($0.26) is undervalued by 24.39% relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PCSA ($0.26) is significantly undervalued by 24.39% relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PCSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PCSA due diligence checks available for Premium users.
Valuation
PCSA fair value
Fair Value of PCSA stock based on Discounted Cash Flow (DCF)
Price
$0.26
Fair Value
$0.34
Undervalued by
23.80%
PCSA ($0.26) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PCSA ($0.26) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PCSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PCSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
-162.28x
Market
29.18x
PCSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
4.45x
PCSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PCSA's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.7M
Profit Margin
0%
PCSA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.2M
Liabilities
$1.5M
Debt to equity
0.9
PCSA's short-term assets ($1.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PCSA's short-term assets ($1.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PCSA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PCSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
$0.0
Financing
$547.6k
PCSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PCSA vs Biotech Stocks
Processa Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.